GlassScriptPhysician profile
Bianca Rebeca Lucaci
NPI 1689331126
$4,167.50
in general payments reported to CMS, 2019-2025
34 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.79 · 2022: $704 · 2023: $888 · 2024: $1,301 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,369 · Travel and Lodging: $22.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,369.41 |
| Travel and Lodging | $22.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $920.71 | 2023-2025 | |
| Novo Nordisk INC | $501.12 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Cvrx, INC. | $405.96 | 2022-2023 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $254.33 | 2022-2025 | Breztri, Airsupra |
| Intra-Sana Laboratories | $222.57 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Pfizer INC. | $212.86 | 2023-2025 | |
| Glaxosmithkline, LLC. | $189.09 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.34 | 2021-2025 | Tradjenta, Jardiance |
| Lilly USA, LLC | $166.86 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $155.88 | 2021-2024 | |
| Mylan Specialty L.P. | $95.43 | 2023-2024 | Yupelri |
| Esperion Therapeutics, INC. | $77.38 | 2022 | |
| Biotronik INC. | $77.25 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $71.93 | 2022 | |
| Amgen INC. | $60.40 | 2023-2024 | Evenity, Repatha, Otezla |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bianca Lucaci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.